Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

February 01, 1997; 48 (2) Article

Pain in Guillain-Barre syndrome

D. E. Moulin, N. Hagen, T. E. Feasby, R. Amireh, A. Hahn
First published February 1, 1997, DOI: https://doi.org/10.1212/WNL.48.2.328
D. E. Moulin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Hagen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. E. Feasby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Amireh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Hahn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Pain in Guillain-Barre syndrome
D. E. Moulin, N. Hagen, T. E. Feasby, R. Amireh, A. Hahn
Neurology Feb 1997, 48 (2) 328-331; DOI: 10.1212/WNL.48.2.328

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
391

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Article abstract-Objectives: To determine the character, intensity and frequency of pain in Guillain-Barre syndrome (GBS) and to evaluate the response to treatment. Design: A prospective longitudinal study. Setting: Academic hospital-based practices. Patients: Fifty-five consecutive patients with GBS. Interventions: Patients were evaluated on admission and at 2, 4, 8, 16, and 24 weeks. Main outcome measures: Character of pain, pain intensity using Visual Analogue Scale ([VAS] 0 to 10 cm) and Present Pain Intensity of McGill Pain Questionnaire, pain relief (VAS 0 to 10 cm), Disability Grading Scale for GBS. Results: Forty-nine patients (89.1%) described pain during the course of their illness. On admission, mean pain intensity (VAS) was 4.7 +/- 3.3. However, 26 patients (47.3%) described pain that was either distressing, horrible, or excruciating (mean VAS, 7.0 +/- 2.0). The most common pain syndromes observed were deep aching back and leg pain and dysesthetic extremity pain. Pain intensity on admission correlated poorly with neurologic disability on admission (r = 0.26, p = 0.06) and throughout the period of study (r < 0.20, p > 0.10). Forty-one patients (74.5%) required opioid analgesics, with 16 (29.0%) receiving parenteral morphine to provide adequate pain relief. Conclusions: Moderate to severe pain is a common and early symptom of GBS and requires aggressive treatment. Pain intensity on admission is not a predictor of poor prognosis. Back and leg pain usually resolves over the first 8 weeks, but dysesthetic extremity pain may persist longer in 5 to 10% of patients despite motor recovery and the use of adjuvant analgesics.

NEUROLOGY 1997;48: 328-331

Although pain is acknowledged as a common symptom in several retrospective reports on Guillain-Barre syndrome (GBS), [1-7] the various pain syndromes seen in GBS often go unrecognized and may be undertreated. Uncontrolled pain can occur despite compassionate and supportive measures such as the use of air mattresses, careful turning of patients and positioning of limbs, and the use of padding over the elbows and knees to prevent pressure palsies. [8] In the only previously published prospective study of pain in GBS, Ropper and Shahani [9] detailed the clinical features and problems of pain in 29 consecutive patients. They described low back and proximal leg pain of muscular origin in 55% of their patients early in the illness and in 72% at some time over the first month. However, there was very little description of other pain syndromes; there was no formal assessment of pain intensity, pain relief, or disability; and follow-up was limited. We report in a prospective longitudinal survey the character, intensity, and frequency of pain in GBS and the response to treatment.

Methods.

The clinical series consisted of 55 consecutive adult patients seen at the University of Western Ontario, London, Ontario, or the University of Calgary, Calgary, Alberta, and diagnosed with GBS according to defined criteria. [10] Four other patients were excluded from analysis because they turned out to have subacute [11] or chronic [12] inflammatory demyelinating polyradiculopathy. Patients were evaluated within 48 hours of admission and at 2, 4, 8, 16, and 24 weeks. Telephone follow-up was obtained when possible for those patients who were unable to keep outpatient appointments. Patients were asked to describe the character of their pain independent of paresthesia and other sensory symptoms. [13] Pain intensity was assessed using a linear Visual Analogue Scale ([VAS] 0 to 10 cm) and the Present Pain Intensity of the McGill Pain Questionnaire. [14] The latter is a categorical scale of pain consisting of the words none, mild, discomforting, distressing, horrible, and excruciating. VAS for pain intensity on admission was correlated with the Disability Grading Scale (Table 1) [15] on admission and at every evaluation time. Treatment was noted, and the response to pain intervention was evaluated using a linear VAS (0 to 10 cm) for pain relief.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Disability Grading Scale

Values are expressed as means +/- SD. Correlations between pain intensity and disability were performed by the Spearman correlation test in which r is the correlation coefficient. Results were considered significant at p < 0.05.

Results.

Patient demographics and clinical characteristics.

Fifty-five consecutive patients with GBS (34 men, 21 women) were followed for a mean of 20.7 weeks +/- 7.1 (SD). Their mean age was 50.6 years. One patient had preexisting diabetes mellitus, and one had mild renal failure. Primary treatment for GBS included plasmapheresis in 30 (54.5%), intravenous immunoglobulin in 13 (23.6%), and both in 8 (14.5%). Thirteen patients (23.6%) required intubation and mechanical ventilation. On admission the mean Disability Grading Scale score was 6.1 +/- 2.0, with 49 patients (89.1%) being moderately disabled (grade 3) or worse. Three patients died during the course of the study-two respirator-dependent patients died of pulmonary sepsis at the ages of 78 and 81, and one patient with Emery-Dreifuss muscular dystrophy died of cardiac complications independent of GBS. At 24 weeks in 45 assessable patients, the mean Disability Grading Scale score was 1.9 +/- 1.8, with 13 patients (28.9%) grade 3 or worse.

Pain was reported by 47 patients (85.5%) on admission. Pain preceded weakness by a mean of 6.1 days in 16 patients, weakness preceded pain by a mean of 5.3 days in 14, and both symptoms appeared simultaneously in seven. Ten patients were unable to report the temporal pattern of pain and weakness. An additional two patients reported new-onset pain during follow-up, so that 49 patients (89.1%) experienced pain attributable to GBS at some time during the course of their illness.

On admission, mean pain intensity (VAS) was 4.7 +/- 3.3. This represents moderate pain despite the fact that many patients had already been given acetaminophen or codeine by the referring physicians or house staff. Pain that was either distressing, horrible, or excruciating was described by 26 patients (47.3%). This subgroup represented a mean pain intensity (VAS) of 7.0 +/- 2.0. Mean pain intensity for the entire group is shown in Figure 1. Pain intensity on admission correlated poorly with neurologic disability on admission (r = 0.26, p = 0.06) and throughout the period of study (r < 0.20, p > 0.10).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Mean pain intensity (+SD) over time in 55 patients with GBS.

Pain syndromes.

Three discrete pain syndromes were observed on admission. Thirty-seven patients (67.3%) described deep aching or throbbing pain in the low back region with radiation into the buttocks, thighs, and occasionally calves. This symptom accounted for most patients who described horrible or excruciating pain. Radiation into the interscapular region occurred in only four of these patients and was never severe. The most striking feature of this pain syndrome was exacerbation by straight leg raising in 32 of 34 patients (94.1%). A second discrete pain syndrome was dysesthetic extremity pain, variously described as burning, tingling, or shock-like; it was present in 11 patients (20%). Dysesthetic pain always involved the legs and about half the time also involved the upper extremities. Myalgic-rheumatic extremity pain was found in five patients (9.1%) on admission. This was aching or crampy pain sometimes associated with joint stiffness. There was local muscle tenderness, and the pain was reproducible with passive range of movement.

Pain syndromes observed in the course of follow-up are shown in Table 2. Aching back and leg pain was still common, but there was an increase in dysesthetic and myalgicrheumatic extremity pain, with considerable overlap between these pain syndromes. Local muscle and joint pain was especially common in association with passive and active-assisted exercises of physiotherapy. Eleven patients (20%) described a pressure-like or bloated sensation in the pelvis or rectal region, which was likely visceral and related to constipation. Suprapubic pain secondary to bladder distension was not observed because the sicker patients were frequently catheterized shortly after admission to treat urinary retention and to facilitate nursing care. During the course of their illness, 20 patients (36.4%) experienced only one pain syndrome, 16 patients (29.1%) experienced two, 8 patients (14.5%) experienced three, and 5 patients (9.1%) had four discrete pain syndromes.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2. Pain syndromes observed in Guillain-Barre syndrome (N = 55)

Pain management and outcome.

Pharmacologic approaches provided the mainstay of treatment. Nonsteroidal anti-inflammatory drugs or acetaminophen were the drugs of first choice for patients who were still able to take oral medications and were used in 28 patients (50.9%). However, 41 patients (74.5%) also required oral or parenteral opioids. Sixteen patients (29.0%) with severe pain were treated with parenteral morphine-10 with intravenous morphine infusions (range, 1 to 7 mg/hr) with superimposed patient-controlled analgesia [16] for breakthrough pain and six with intermittent subcutaneous injections to supplement oral opioids (codeine, oxycodone, or morphine). All patients were weaned off opioid drugs within 12 weeks, most within 8 weeks, and none showed any evidence of psychological dependence or addiction. Opioid analgesics did not appear to contribute to respiratory depression in non-ventilated patients. Six patients (10.9%) were treated with tricyclic antidepressants, and five (9.1%) with other adjuvant analgesics such as carbamazepine and quinine.

Pain relief gradually improved with analgesic intervention and resolution of the disease process. Mean pain relief (VAS 0 to 10 cm) was 6.9 +/- 3.1 at 2 weeks and 9.5 +/- 1.4 at 24 weeks. Somatic back and extremity pain had resolved in most patients by 8 weeks. Dysesthetic extremity pain tended to linger, but had resolved in all but two patients at 24 weeks-these patients had persistent dysesthetic pain despite motor recovery. Their pain was described as "distressing," and the pain intensity (VAS 0 to 10 cm) was rated at 5.0 and 7.3. Six other patients described "mild" extremity pain of a myalgic-rheumatic nature that was easily relieved with aspirin or acetaminophen.

Discussion.

The most striking finding of this study was that back and leg pain of a moderate to severe nature was a presenting symptom in almost half our patients with GBS. Recognition of this problem is especially important in a disease that may immobilize patients and require intubation so that patients are unable to communicate their distress. However, we did not find a correlation between pain on admission and subsequent disability, unlike a previous suggestion [9]; patients with significant pain do not necessarily progress to severe paralysis or have a poor prognosis.

The etiology of back and leg pain in GBS is likely multifactorial. During the acute stage, muscles that are becoming paralyzed are commonly painful. Although we did not routinely measure serum creatinine kinase, Ropper and Shahani [9] found that this enzyme was consistently elevated in patients with painful muscles. Our finding that acute back and leg pain was commonly exacerbated by straight leg raising provides indirect evidence that traction on inflamed nerve roots [2] could be responsible for some of the pain. Sciatica in GBS can lead to a misdiagnosis of acute radiculopathy caused by herniated disk. [9,17] However, pain exacerbation by nerve root traction maneuvers is so characteristic of GBS that it actually aids in the diagnosis of this syndrome. Irritation of the nervi nervorum, which innervates nerve trunks, [18] may also refer pain to the paraspinal region via the dorsal primary rami.

Although none of our patients received corticosteroids, methylprednisolone may relieve severe muscle pain in GBS, [19] and this may be due to its anti-inflammatory effects at the nerve root level. During the recovery phase of GBS, muscle and joint pain is common but may not be as severe as in the acute stage. We speculate that persistent muscle and joint pain may be related to mechanical factors; one report suggests that weakness of the paraspinal musculature can lead to poor posture and abnormal mechanical forces on the spine that can prolong back pain. [20] Although a program of passive and active-assisted exercises is crucial to prevent contractures and regain strength, range-of-motion exercises are frequently painful in the setting of weak muscles and stiff joints.

We relied frequently on oral and parenteral opioid analgesics to treat somatic back and extremity pain; this strategy was effective in most patients. Several patients placed on intravenous morphine infusions in the intensive care unit later described this intervention as being vital to their recovery. This is in contrast to the report of Ng et al. [7] who stated that opioid analgesics had limited value in ventilated patients. Starting doses of sustained-release oral morphine were in the range of 30 to 60 mg bid. Starting doses of intravenous morphine infusion were usually in the range of 1 to 3 mg/hr and reached a maximum of 7 mg/hr.

Opioid drugs were generally well tolerated. Respiratory depression is always a concern in non-ventilated GBS patients, but careful dose titration and screening of vital capacity and respiratory rate minimizes the risk. Psychological dependence or addiction was never an issue during opioid withdrawal. None of our patients had a history of drug abuse, and in such a population the risk of iatrogenic addition is extremely low. [21] Opioid analgesics probably contributed to constipation in our patients despite the use of an aggressive bowel regimen involving bowel stimulants and stool softeners. We did not employ epidural morphine, but it would be an acceptable alternative to systemic opioids in ventilated patients with primarily low back and leg pain in the acute phase of the disease. [22,23] Spinal opioids can produce profound analgesia in small doses without motor, sensory, or autonomic effects. [24]

In summary, patients with GBS require close monitoring for pain and aggressive use of analgesic agents for those with moderate to severe pain.

Acknowledgments

We thank Sue Kimber, RN, and Peggy Vandervoort, RN, for clinical assistance and data collection and Anthony Iezzi, PhD, for statistical support.

  • Copyright 1997 by Advanstar Communications Inc.

REFERENCES

  1. 1.↵
    Haymaker W, Kernohan JW. Landry-Guillain-Barre syndrome: a clinicopathological report of fifty fatal cases and a critique of the literature. Medicine 1949;28:59-141.
    OpenUrl
  2. 2.↵
    Asbury A, Arnason B, Adams RD. The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine 1969;48:173-215.
    OpenUrlPubMed
  3. 3.
    Loffel NB, Rossi LN, Mumenthaler M, Lutschg J, Ludin HP. The Landry-Guillain-Barre syndrome: complications, prognosis, and natural history in 123 cases. J Neurol Sci 1977;33:71-79.
    OpenUrl
  4. 4.
    Samantray SK, Johnson SC, Mathai KV, Pulimood BM. Landry-Guillain-Barre syndrome: a study of 302 cases. Med J Aust 1977;2:84-91.
    OpenUrlPubMed
  5. 5.
    Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51:605-612.
    OpenUrl
  6. 6.
    De Jager AE, Sluiter HJ. Clinical signs in severe Guillain-Barre syndrome: analysis of 63 patients. J Neurol Sci 1991;104:143-150.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Ng KKP, Howard RS, Fish DR, et al. Management and outcome of severe Guillain-Barre syndrome. Q J Med 1995;88:243-250.
    OpenUrl
  8. 8.↵
    Hughes RAC, Winer JB. Guillain-Barre syndrome. In: Matthews WB, Glaser GH, eds. Recent advances in clinical neurology, vol 4. Edinburgh: Churchill Livingstone, 1984:19-49.
  9. 9.↵
    Ropper AH, Shahani BT. Pain in Guillain-Barre syndrome. Arch Neurol 1984;41:511-514.
    OpenUrl
  10. 10.↵
    Asbury AK. Diagnostic considerations in Guillain-Barre syndrome. Ann Neurol 1981;9(suppl):1-5.
  11. 11.↵
    Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992;49:612-616.
    OpenUrl
  12. 12.↵
    Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1991;41:617-618.
    OpenUrl
  13. 13.↵
    Merskey H, Albe-Fessard DG, Bonica JJ, et al. Pain terms: a list with definitions and notes on usage. Pain 1979;6:249-252.
    OpenUrl
  14. 14.↵
    Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-299.
    OpenUrlPubMed
  15. 15.↵
    Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, crossover study. Brain 1996;119:1055-1066.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Graves DA, Foster TS, Batenhorst RL, Bennett RL, Baumann TJ. Patient-controlled analgesia. Ann Intern Med 1983;99:360-366.
    OpenUrl
  17. 17.
    Clague JE, MacMillan RR. Backache and the Guillain-Barre syndrome: a diagnostic problem. BMJ 1986;293:325-326.
    OpenUrlFREE Full Text
  18. 18.↵
    Asbury AK, Fields HL. Pain due to peripheral nerve damage: an hypothesis. Neurology 1984;34:1587-1590.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barre syndrome. Philadelphia: FA Davis, 1991.
  20. 20.↵
    Pentland B, Donald SM. Pain in the Guillain-Barre syndrome: a clinical review. Pain 1994;59:159-164.
    OpenUrlPubMed
  21. 21.↵
    Moulin DE, Iezzi A, Amireh R, Sharpe WKJ, Boyd D, Merskey H. Randomized trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-147.
    OpenUrlPubMed
  22. 22.↵
    Rosenfeld B, Borel C, Hanley D. Epidural morphine treatment of pain in Guillain-Barre syndrome. Arch Neurol 1986;43:1194-1196.
    OpenUrl
  23. 23.
    Genis D, Busquets C, Manubens E, Davalos A, Baro J, Oterino A. Epidural morphine analgesia in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1989;52:999-1001.
    OpenUrl
  24. 24.↵
    Yaksh TL. Spinal opiate analgesia: characteristics and principles of action. Pain 1981;11:293-346.
    OpenUrlFREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise